Clinical trial · Observational
Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients
Pyrotinib Plus Vinorelbine in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study
NCT04517305CI-TRIAL-00052316completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Pyrotinib plus vinorelbine
- description
- Patients used pyrotinib plus vinorelbine as treatment for metastatic breast cancer.
Primary outcomes (2)
- measure
- PFS
- timeFrame
- 6 weeks
- description
- Progression free survival
- measure
- Adverse events
- timeFrame
- 6 weeks
- description
- Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * woman, age \> 18 years old * diagnosed with HER2 +Metastatic Breast Cancer * pyrotinib plus vinorelbine for at least one cycle, starting from 2018.05-2020.05 * available medical history Exclusion Criteria: * medical history was incomplete
References
Publications (1)
- DERIVEDLi Y, Qiu Y, Li H, Luo T, Li W, Wang H, Shao B, Wang B, Ge R. Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study. Front Oncol. 2021 Apr 20;11:664429. doi: 10.3389/fonc.2021.664429. eCollection 2021. PMID 33996589